2022 World Conference on Lung Cancer (ePosters)-EP02.03-009. Real-world Disease-Free Survival as a Predictor of Overall Survival in Resected Early-Stage Non-Small Cell Lung Cancer

EP02.03-009. Real-world Disease-Free Survival as a Predictor of Overall Survival in Resected Early-Stage Non-Small Cell Lung Cancer

Back to course

Pdf Summary

This document is a summary of a study that evaluated the real-world impact of disease recurrence on the health-care resource utilization (HCRU), health-care costs, and overall survival (OS) among patients with resected early-stage non-small-cell lung cancer (NSCLC). The study used data from the Surveillance, Epidemiology, and End Results (SEER)-Medicare database and included patients who underwent primary surgery for stage IB-IIIA NSCLC. Patients were assigned to either a recurrence cohort or a nonrecurrence cohort based on whether they experienced recurrence after surgery.<br /><br />The study found that patients with NSCLC recurrence had a significantly higher risk of death and incurred more HCRU and health-care costs than patients without recurrence. The recurrence cohort had higher rates of NSCLC-related inpatient admissions and outpatient visits, and higher mean monthly all-cause and NSCLC-related health-care costs compared to the nonrecurrence cohort.<br /><br />Furthermore, the study showed that disease-free survival (rwDFS) and OS were significantly correlated among patients with early-stage NSCLC. Patients with recurrence had shorter OS from the index date and a higher risk of death at each landmark timepoint post-surgery compared to those without recurrence.<br /><br />The limitations of the study include its retrospective observational design using administrative claims data, which may lead to misclassification bias and potential confounding by unmeasured characteristics. Additionally, the study only included Medicare patients aged 65 years and older, so the results may not be generalizable to a younger patient population.<br /><br />Overall, these findings highlight the need for novel therapies to prevent or delay recurrence in patients with resected early-stage NSCLC in order to improve survival outcomes and reduce the burden on healthcare resources and costs.

Asset Subtitle

Howard (Jack) West

Meta Tag

Speaker Howard (Jack) West

Topic Early Stage Non-small Cell Lung Cancer - Surgery

Keywords

disease recurrence

health-care resource utilization

health-care costs

overall survival

non-small-cell lung cancer

NSCLC

Surveillance, Epidemiology, and End Results

SEER-Medicare database

primary surgery

stage IB-IIIA